HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo

doi:10.1186/1479-0556-5-10

Genetic Vaccines and Therapy

Volume 5

Viewing options:

Abstract
Full text
PDF (570KB)
Additional files

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Segura-Pacheco B
Avalos B
Rangel E
Velazquez D
Cabrera G

on PubMed

Segura-Pacheco B
Avalos B
Rangel E
Velazquez D
Cabrera G
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo

Blanca Segura-Pacheco^* , Berenice Avalos^* , Edgar Rangel , Dora Velazquez and Gustavo Cabrera

Vectorology and Gene Therapy Laboratory, National Cancer Institute, Av. San Fernando No 22, Del. Tlalpan, CP 14080, Mexico City, Mexico

author email corresponding author email* Contributed equally

Genetic Vaccines and Therapy 2007, 5:10doi:10.1186/1479-0556-5-10


Published:	24 September 2007

Additional files

Additional file 1:

"VPA mediated CAR transcriptional induction enhances adenoviral transgene expression on HeLa, T24 and MCF7 cell lines." Data corresponds to Figure 3, Panel B. In triplicate, cells were treated with VPA as described in methods. Twenty four hours after pharmacological treatment cells were then transduced for 1 hour with Ad.CMV.Luc. 48 hours post adenoviral transduction cells were harvested and assayed for luciferase activity. Asterisks indicate statistically significant changes among control vs VPA groups (p < 0.05).

Format: XLS Size: 33KB Download file

This file can be viewed with: Microsoft Excel Viewer